Logo image of ONCS

OncoSec Medical Incorporated (ONCS) Stock Fundamental Analysis

NASDAQ:ONCS - Nasdaq - US68234L4059 - Common Stock - Currency: USD

0.2772  +0.07 (+31.87%)

After market: 0.23 -0.05 (-17.03%)

Fundamental Rating

0

Overall ONCS gets a fundamental rating of 0 out of 10. We evaluated ONCS against 566 industry peers in the Biotechnology industry. ONCS may be in some trouble as it scores bad on both profitability and health. ONCS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ONCS had negative earnings in the past year.
In the past year ONCS has reported a negative cash flow from operations.
In the past 5 years ONCS always reported negative net income.
ONCS had a negative operating cash flow in each of the past 5 years.
ONCS Yearly Net Income VS EBIT VS OCF VS FCFONCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

The profitability ratios for ONCS are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ONCS Yearly ROA, ROE, ROICONCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCS Yearly Profit, Operating, Gross MarginsONCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for ONCS has been increased compared to 1 year ago.
ONCS has a worse debt/assets ratio than last year.
ONCS Yearly Shares OutstandingONCS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
ONCS Yearly Total Debt VS Total AssetsONCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

ONCS has an Altman-Z score of -59.67. This is a bad value and indicates that ONCS is not financially healthy and even has some risk of bankruptcy.
ONCS has a worse Altman-Z score (-59.67) than 92.77% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -59.67
ROIC/WACCN/A
WACCN/A
ONCS Yearly LT Debt VS Equity VS FCFONCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

ONCS has a Current Ratio of 0.89. This is a bad value and indicates that ONCS is not financially healthy enough and could expect problems in meeting its short term obligations.
ONCS has a worse Current ratio (0.89) than 88.91% of its industry peers.
A Quick Ratio of 0.89 indicates that ONCS may have some problems paying its short term obligations.
ONCS has a worse Quick ratio (0.89) than 87.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.89
ONCS Yearly Current Assets VS Current LiabilitesONCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

ONCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.16%, which is quite impressive.
EPS 1Y (TTM)39.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.37%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCS Yearly EPS VS EstimatesONCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONCS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCS Price Earnings VS Forward Price EarningsONCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCS Per share dataONCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ONCS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OncoSec Medical Incorporated

NASDAQ:ONCS (6/23/2023, 8:00:02 PM)

After market: 0.23 -0.05 (-17.03%)

0.2772

+0.07 (+31.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-15 2023-06-15/amc
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners49.44%
Ins Owner Change0%
Market Cap1.65M
Analysts43.33
Price Target5.1 (1739.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.96%
Min EPS beat(2)9.96%
Max EPS beat(2)9.96%
EPS beat(4)3
Avg EPS beat(4)12.34%
Min EPS beat(4)9.96%
Max EPS beat(4)14.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-19.14
EYN/A
EPS(NY)-2.42
Fwd EYN/A
FCF(TTM)-4.19
FCFYN/A
OCF(TTM)-4.19
OCFYN/A
SpS0
BVpS-0.92
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.89
Altman-Z -59.67
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
EPS Next Y87.37%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.52%
OCF growth 3YN/A
OCF growth 5YN/A